Medeon Biodesign, Inc. (TPEX:6499)

Market Cap	9.04B +125.1%
Revenue (ttm)	419.43M +43.2%
Net Income	-668.06M
EPS	-7.24
Shares Out	96.94M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	759,485
Average Volume	1,784,027
Open	96.50
Previous Close	97.20
Day's Range	93.30 - 96.50
52-Week Range	34.75 - 154.50
Beta	0.81
RSI	46.57
Earnings Date	May 8, 2026

About Medeon Biodesign

Medeon Biodesign, Inc. engages in the research and development, manufacturing, and sale of medical devices in the United States. The company focuses on developing devices for minimally invasive surgeries, such as Cross-Seal, a large bore vascular closure system; Urocross, an expander system for treating lower urinary tract symptoms associated with benign prostatic hyperplasia; Duett, a vascular graft system; PUMA, solution to treat orthopedic extremity injuries; ClickClean, a solution to view throughout laparoscopic surgeries; and AbClose to pr...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2012
• Employees: 39
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6499

Financial Performance

In 2025, Medeon Biodesign's revenue was 419.43 million, an increase of 43.24% compared to the previous year's 292.81 million. Losses were -668.06 million, -17.06% less than in 2024.